Results 41 to 50 of about 737 (141)

Lactate dehydrogenase predicts disease progression outcome in COVID-19 patients treated with Azvudine

Frontiers in Cellular and Infection Microbiology, 2023
BackgroundAzvudine has been approved in China for the treatment of COVID-19 patients. Previous studies have suggested a correlation between high levels of lactate dehydrogenase (LDH) and the severity of COVID-19.
Manyun Mao, Manyun Mao, Manyun Mao, Manyun Mao, Manyun Mao, Yating Dian, Yating Dian, Yating Dian, Yating Dian, Yating Dian, Yuming Sun, Yuming Sun, Yuming Sun, Yuming Sun, Yuming Sun, Wangqing Chen, Wangqing Chen, Wangqing Chen, Wangqing Chen, Wangqing Chen, Wu Zhu, Wu Zhu, Wu Zhu, Wu Zhu, Wu Zhu, Guangtong Deng, Guangtong Deng, Guangtong Deng, Guangtong Deng, Guangtong Deng   +29 more
doaj   +3 more sources

Evaluation of the efficacy and mechanisms of azvudine in elderly patients with malignant tumors complicated by COVID-19. [PDF]

Acta Pharm Sin B
Sun R, Song Y, Li Z, Wang D, Yu Z.
europepmc   +6 more sources

Real-world effectiveness of azvudine versus nirmatrelvir-ritonavir in hospitalized patients with COVID-19 and pre-existing diabetes [PDF]

iScience
Summary: Azvudine and nirmatrelvir-ritonavir are prioritized treatments for SARS-CoV-2 infection in China, but their effectiveness and safety in hospitalized patients with COVID-19 and pre-existing diabetes remains unknown.
Guanyue Su, Silin Li, Donghua Zhang, Yongjian Zhou, Ling Wang, Yiqiang Yuan, Guowu Qian, Guotao Li, Na Han, Ming Cheng, Guangming Li, Shixi Zhang, Hong Luo, Mengzhao Yang, Yanyang Zhang, Zhan Song, Jiyuan Xing, Zujiang Yu, Zhigang Ren   +18 more
doaj   +2 more sources

Antiviral effectiveness and safety of azvudine in hospitalized SARS‐CoV‐2 patients with pre‐existing chronic respiratory diseases: A multicenter, retrospective cohort study

View
Although azvudine has become a priority in the treatment of SARS‐CoV‐2, its effectiveness and safety among COVID‐19 patients who already have chronic respiratory diseases (CRDs) have not been sufficiently validated.
Junyi Sun, Mengzhao Yang, Daoke Yao, Yongjian Zhou, Xiaobo Hu, Guowu Qian, Yiqiang Yuan, Silin Li, Hong Luo, Shixi Zhang, Guangming Li, Donghua Zhang, Guotao Li, Yanyang Zhang, Xinjun Hu, Zujiang Yu, Guangying Cui, Zhigang Ren   +17 more
doaj   +2 more sources

Azvudine versus paxlovid for oral treatment of COVID-19 in Chinese patients

BMC Infectious Diseases
Purpose To explore the effect of azvudine as compared to paxlovid for oral treatment of hospitalized patients with SARS-CoV-2 infection. Methods We analyzed data from a cohort of patients with SARS-CoV-2 infection in Shandong provincial hospital between ...
Peng Su, Cong-xian Yang, Xing-guang Wang
doaj   +3 more sources

Effectiveness of nirmatrelvir-ritonavir versus azvudine for adult inpatients with severe or critical COVID-19

BMJ Open Respiratory Research
Background In China, both nirmatrelvir-ritonavir (Paxlovid) and azvudine have been granted approval to treat adult SARS-CoV-2-infected patients with moderate symptoms.
Junjun Chen, Zheng Zhang, Huan Zhang, Yao Li, Yan Kang, Jianbo Li, Tan Xiaojiao, Chenxi Wang, Haiqing Shi, Xiaodong Jin, Xuelian Liao   +10 more
doaj   +3 more sources

Efficacy of azvudine plus dexamethasone in severe hospitalized patients with Omicron infection: a prospective multicenter study. [PDF]

Front Cell Infect Microbiol
BackgroundAzvudine (AZV), the first Chinese oral anti-coronavirus disease 2019 (COVID-19) drug, has shown substantial clinical benefits to viral clearance and prognosis in patients with mild and common COVID-19. However, there is no evidence in severe hospitalized COVID-19 patients.MethodsIn this multicenter study, we analyzed 209 severe hospitalized ...
Zhang ML, Wei XY, Su N, Jiang JH, Xu GP, Zeng DX.   +5 more
europepmc   +7 more sources

Validation study for assessing COVID-19 pneumonia treatments [PDF]

Scientific Reports
This study investigates the effectiveness of Azvudine and nirmatrelvir-ritonavir (Paxlovid) in treating COVID-19 pneumonia through an analysis of real-world clinical data.
Kaibin Lin, Bing Zhou, Yi Wu, Zheng Wang, Shu Li, Yuanyuan Li, Fen Li, Yang Xue, Zirou Liu, Jiafen Liao   +9 more
doaj   +2 more sources

Azvudine Suppresses Epithelial–Mesenchymal Transition in Hepatocellular Carcinoma by Targeting the Notch–HEY Signalling Pathway [PDF]

International Journal of Molecular Sciences
Azvudine (FNC) is a novel cytidine analogue that is widely used in the treatment of infectious diseases such as AIDS and COVID-19. Previous studies have demonstrated its anticancer activity in various cancer cell lines, including non-Hodgkin’s lymphomas and lung adenocarcinoma cell lines.
Yao Meng, Peiyi Sun, Yixin Ren, Guoqing Li, Xiujun Liu, Chunjie Xu, Luyao Dong, Hanhan Li, Zhonghui Zheng, Xuefu You, Xinyi Yang   +10 more
openaire   +3 more sources

Azvudine potently inhibits African swine fever virus replication in vitro. [PDF]

Virus Res
African swine fever (ASF), caused by the African swine fever virus (ASFV), is a highly contagious and often fatal disease affecting domestic pigs and wild boars, resulting in substantial economic losses globally. The lack of commercially available vaccines or effective antiviral drugs highlights the urgent need for novel therapeutic strategies. In this
Xi F, Sun B, Duan L, Lu B, Zhang S, Tian H, Yang F, Zhu Z, Zheng H, Zhu G, Tang L.   +10 more
europepmc   +4 more sources